6G77

RSK4 N-terminal Kinase Domain in complex with AMP-PNP


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.50 Å
  • R-Value Free: 0.233 
  • R-Value Work: 0.185 
  • R-Value Observed: 0.188 

wwPDB Validation   3D Report Full Report


Ligand Structure Quality Assessment 


This is version 1.2 of the entry. See complete history


Literature

Repurposed floxacins targeting RSK4 prevent chemoresistance and metastasis in lung and bladder cancer.

Chrysostomou, S.Roy, R.Prischi, F.Thamlikitkul, L.Chapman, K.L.Mufti, U.Peach, R.Ding, L.Hancock, D.Moore, C.Molina-Arcas, M.Mauri, F.Pinato, D.J.Abrahams, J.M.Ottaviani, S.Castellano, L.Giamas, G.Pascoe, J.Moonamale, D.Pirrie, S.Gaunt, C.Billingham, L.Steven, N.M.Cullen, M.Hrouda, D.Winkler, M.Post, J.Cohen, P.Salpeter, S.J.Bar, V.Zundelevich, A.Golan, S.Leibovici, D.Lara, R.Klug, D.R.Yaliraki, S.N.Barahona, M.Wang, Y.Downward, J.Skehel, J.M.Ali, M.M.U.Seckl, M.J.Pardo, O.E.

(2021) Sci Transl Med 13

  • DOI: 10.1126/scitranslmed.aba4627
  • Primary Citation of Related Structures:  
    6G77, 6G76, 6G78

  • PubMed Abstract: 
  • Lung and bladder cancers are mostly incurable because of the early development of drug resistance and metastatic dissemination. Hence, improved therapies that tackle these two processes are urgently needed to improve clinical outcome. We have identified RSK4 as a promoter of drug resistance and metastasis in lung and bladder cancer cells ...

    Lung and bladder cancers are mostly incurable because of the early development of drug resistance and metastatic dissemination. Hence, improved therapies that tackle these two processes are urgently needed to improve clinical outcome. We have identified RSK4 as a promoter of drug resistance and metastasis in lung and bladder cancer cells. Silencing this kinase, through either RNA interference or CRISPR, sensitized tumor cells to chemotherapy and hindered metastasis in vitro and in vivo in a tail vein injection model. Drug screening revealed several floxacin antibiotics as potent RSK4 activation inhibitors, and trovafloxacin reproduced all effects of RSK4 silencing in vitro and in/ex vivo using lung cancer xenograft and genetically engineered mouse models and bladder tumor explants. Through x-ray structure determination and Markov transient and Deuterium exchange analyses, we identified the allosteric binding site and revealed how this compound blocks RSK4 kinase activation through binding to an allosteric site and mimicking a kinase autoinhibitory mechanism involving the RSK4's hydrophobic motif. Last, we show that patients undergoing chemotherapy and adhering to prophylactic levofloxacin in the large placebo-controlled randomized phase 3 SIGNIFICANT trial had significantly increased ( P = 0.048) long-term overall survival times. Hence, we suggest that RSK4 inhibition may represent an effective therapeutic strategy for treating lung and bladder cancer.


    Organizational Affiliation

    Division of Cancer, Department of Surgery and Cancer, Imperial College London, London SW7 2AZ, UK. maruf.ali@imperial.ac.uk m.seckl@imperial.ac.uk o.pardo@imperial.ac.uk.



Macromolecules
Find similar proteins by:  (by identity cutoff)  |  Structure
Entity ID: 1
MoleculeChainsSequence LengthOrganismDetailsImage
Ribosomal protein S6 kinase alpha-6A, B307Homo sapiensMutation(s): 0 
Gene Names: RPS6KA6RSK4
EC: 2.7.11.1
UniProt & NIH Common Fund Data Resources
Find proteins for Q9UK32 (Homo sapiens)
Explore Q9UK32 
Go to UniProtKB:  Q9UK32
PHAROS:  Q9UK32
Protein Feature View
Expand
  • Reference Sequence
Small Molecules
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.50 Å
  • R-Value Free: 0.233 
  • R-Value Work: 0.185 
  • R-Value Observed: 0.188 
  • Space Group: P 1 21 1
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 51.143α = 90
b = 113.916β = 90.24
c = 62.183γ = 90
Software Package:
Software NamePurpose
PHENIXrefinement
PDB_EXTRACTdata extraction
XDSdata reduction
Aimlessdata scaling
PHASERphasing

Structure Validation

View Full Validation Report



Ligand Structure Quality Assessment  



Entry History & Funding Information

Deposition Data

  • Deposited Date: 2018-04-04 
  • Released Date: 2019-04-17 
  • Deposition Author(s): Prischi, F., Ali, M.M.

Funding OrganizationLocationGrant Number
Cancer Research UKUnited KingdomC33269/A11161

Revision History  (Full details and data files)

  • Version 1.0: 2019-04-17
    Type: Initial release
  • Version 1.1: 2021-07-28
    Changes: Database references, Derived calculations
  • Version 1.2: 2021-08-11
    Changes: Database references